Business Context and Reporting Period
This Form 8-K is a current report filed by Graphite Bio, Inc. (not Lenz Therapeutics, Inc., as indicated in the metadata) on June 23, 2023. The filing reports the resignation of the company's Chief Financial Officer and the appointment of the CEO to interim financial leadership roles.
Key Financial Metrics
This filing is a current report regarding corporate governance and personnel changes. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. No financial metrics are provided in this document.
Material Changes
- Departure of CFO: Alethia Young, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer, resigned effective June 30, 2023.
- Reason for Departure: The resignation is not related to any disagreement with the Company, its management, or the Board regarding operations, policies, or practices.
- Interim Appointment: Josh Lehrer, the Company's Chief Executive Officer, was appointed to serve as the Principal Financial Officer and Principal Accounting Officer effective immediately following Ms. Young's departure.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, operational outlook, or specific risk factors beyond the standard disclosure of executive turnover. The press release referenced in Item 7.01 is not incorporated by reference into this filing.
Key Facts for Investor Verification
- Verify the transition plan for the Chief Financial Officer role beyond the interim appointment of the CEO.
- Confirm the effective date of the CFO resignation (June 30, 2023) and the immediate assumption of duties by the CEO.
- Review the referenced press release (Exhibit 99.1) for any additional context not included in the 8-K text.
- Note that the metadata company name "LENZ Therapeutics, Inc." is incorrect; the filing is for Graphite Bio, Inc. (Ticker: GRPH).